Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (9.999.253 €): Ein virtueller Zwilling der CEllulaR immunoTherapy für die personalisierte Krebsbehandlung Hor 01.12.2023 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Ein virtueller Zwilling der CEllulaR immunoTherapy für die personalisierte Krebsbehandlung

"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy. The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem. To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process. Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."


Geförderte Unternehmen:

Firmenname Förderungssumme
F. Hoffmann-LA Roche AG ?
Charite - Universitaetsmedizin Berlin 166.730 €
Collaborate Project Management GmbH 233.423 €
European Society FOR Blood AND Marrow Transplantation 1.071.585 €
Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. 2.429.610 €
Healthtree Foundation Inc. 668.430 €
Helmholtz-Zentrum Dresden-Rossendorf e. V. 280.828 €
Information Technology FOR Translational Medicine (Ittm) SA 632.384 €
Institut Curie 435.643 €
Masarykova Univerzita 564.221 €
Myeloma Patients Europe Aisbl 101.994 €
Singleron Biotechnologies GmbH 571.646 €
Trinetx Oncology GmbH 100.038 €
Universitaet Leipzig 1.715.059 €
Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat 157.404 €
Universitair Medisch Centrum Utrecht 465.986 €
Universite de Namur 404.274 €

Quelle: https://cordis.europa.eu/project/id/101136379

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: F. Hoffmann-La Roche AG, Basel, Schweiz.